From GlobeNewswire: 2025-06-13 16:52:00

Vaxart, Inc. held its Annual Meeting of Stockholders in a virtual format, where two proposals were approved and two were rejected. Stockholders voted in favor of electing six director nominees and ratifying Vaxart’s independent registered public accounting firm. However, they voted against a proposal for a reverse stock split and executive compensation. Final results are pending verification by the inspector of elections and will be reported in a Form 8-K filed with the SEC.

Vaxart is a biotech company developing oral recombinant vaccines, including those for coronavirus, norovirus, and influenza. Its proprietary pill vaccine delivery platform eliminates the need for refrigeration and needle-stick injuries. The company has filed patent applications for its technology, covering oral vaccination using adenovirus and TLR3 agonists. Note that forward-looking statements in this press release are subject to risks and uncertainties. Contact Vaxart’s Media and Investor Relations for more information.



Read more at GlobeNewswire: Vaxart Announces Preliminary Results of Annual Meeting of